Physician profile
Victoria Helena Fierro-Cobas
NPI 1801882899
$1,231.65
in general payments reported to CMS, 2019-2025
12 companies · $977 in 2025
The $977 reported for 2025 was more than what 90% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.66 · 2024: $226 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $378.57 | 2024-2025 | Qelbree |
| Ucb, INC. | $354.08 | 2025 | Nayzilam, Briviact |
| Sanofi-Aventis U.S. LLC | $160.17 | 2024-2025 | |
| Corium, LLC | $112.81 | 2025 | Azstarys |
| Neurelis, INC. | $47.03 | 2025 | Valtoco |
| Harmony Biosciences LLC | $36.45 | 2025 | |
| Cranial Technologies, INC | $29.53 | 2019-2024 | Doc Band |
| Azurity Pharmaceuticals, INC. | $27.63 | 2025 | Zonisade |
| Tris Pharma INC | $25.94 | 2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $22.22 | 2025 | |
| Collegium Pharmaceutical, INC. | $21.60 | 2025 | Jornay Pm |
| Amneal Pharmaceuticals LLC | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Fierro-Cobas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.